tucatinib,,trastuzumab deruxtecan
seagen,daiichi sankyo,astrazeneca
['bcsm', 'breast', 'tucatinib']
so the panel at #asco22 for metastatic her2 positive breast cancer recommends 1l cleopatra; 2l tdxd; 3l tucatinib/cape/trast. we don t have the latter 2 lines available in australia. the science is moving fast. #bcsm
Medical Oncologist, clinician researcher. Views are my own.